Synonyms: LY-3039478 | LY3039478
Compound class:
Synthetic organic
|
|
References |
1. Abdel-Magid AF. (2013)
Inhibition of notch pathway signaling: a one compound mission to treat cancer. ACS Med Chem Lett, 4 (4): 373-4. [PMID:24900678] |
2. Borthakur G, Martinelli G, Raffoux E, Chevallier P, Chromik J, Lithio A, Smith CL, Yuen E, Oakley 3rd GJ, Benhadji KA et al.. (2021)
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer, 127 (3): 372-380. [PMID:33107983] |
3. Even C, Lassen U, Merchan J, Le Tourneau C, Soria JC, Ferte C, Ricci F, Diener JT, Yuen E, Smith C et al.. (2020)
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest New Drugs, 38 (2): 402-409. [PMID:30953269] |
4. Mancarella S, Serino G, Dituri F, Cigliano A, Ribback S, Wang J, Chen X, Calvisi DF, Giannelli G. (2020)
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. Cell Death Differ, 27 (8): 2330-2343. [PMID:32042099] |
5. Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR et al.. (2018)
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol, 29 (9): 1911-1917. [PMID:30060061] |